Optic neuropathy in patients with glioblastoma receiving bevacizumab.
作者信息
Sherman J H, Aregawi D G, Lai A, Fathallah-Shaykh H M, Bierman P J, Linsky K, Larner J M, Newman S A, Schiff D
机构信息
Departments of Neurological Surgery,University of Virginia, Charlottesville, VA 22908, USA.
出版信息
Neurology. 2009 Dec 1;73(22):1924-6. doi: 10.1212/WNL.0b013e3181c3fd00.
Abstract
摘要
相似文献
1
Optic neuropathy in patients with glioblastoma receiving bevacizumab.接受贝伐单抗治疗的胶质母细胞瘤患者的视神经病变
Neurology. 2009 Dec 1;73(22):1924-6. doi: 10.1212/WNL.0b013e3181c3fd00.
2
Optic neuropathy in patients with glioblastoma receiving bevacizumab.接受贝伐单抗治疗的胶质母细胞瘤患者的视神经病变
Neurology. 2010 Jul 20;75(3):289-90; author reply 290. doi: 10.1212/WNL.0b013e3181e79567.
3
Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.一名接受贝伐单抗治疗多形性胶质母细胞瘤的患者出现了痤疮样皮疹。
Arch Dermatol. 2010 May;146(5):577. doi: 10.1001/archdermatol.2010.68.
4
Ipilimumab and Bevacizumab in Glioblastoma.伊匹单抗和贝伐单抗治疗胶质母细胞瘤
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):622-626. doi: 10.1016/j.clon.2016.04.042. Epub 2016 May 8.
5
Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?贝伐单抗抗血管生成疗法在胶质母细胞瘤中迅速应用之谜：恶性脑肿瘤治疗的新时代？
Acta Oncol. 2009;48(1):6-8. doi: 10.1080/02841860802468112.
6
Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.贝伐单抗用于治疗肾细胞癌、胶质母细胞瘤及其他实体瘤。
Oncology (Williston Park). 2009 Oct;23(11 Suppl Nurse Ed):54-6.
7
Bevacizumab antiangiogenic therapy for glioblastoma.贝伐单抗用于胶质母细胞瘤的抗血管生成治疗。
Neurology. 2011 Feb 1;76(5):414-5. doi: 10.1212/WNL.0b013e31820a0d7e.
8
World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.世界首例将动脉内注射贝伐单抗直接用于多形性胶质母细胞瘤患者的脑肿瘤治疗。
Expert Rev Anticancer Ther. 2010 Jan;10(1):5. doi: 10.1586/era.09.181.
9
Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.贝伐珠单抗治疗胶质母细胞瘤后发生脊髓转移。
Target Oncol. 2013 Jun;8(2):153-5. doi: 10.1007/s11523-013-0270-0. Epub 2013 Feb 21.
10
First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?胶质母细胞瘤的一线贝伐单抗治疗：近期试验结果对未来治疗意味着什么？
CNS Oncol. 2013 Nov;2(6):473-4. doi: 10.2217/cns.13.41.
引用本文的文献
1
Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.新型抗癌药物对眼后段的副作用：文献综述
J Pers Med. 2024 Dec 19;14(12):1160. doi: 10.3390/jpm14121160.
2
Neuro-ophthalmic complications of modern anti-cancer drugs.现代抗癌药物的神经眼科并发症。
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2269-2281. doi: 10.1007/s00417-023-06350-4. Epub 2024 Feb 12.
3
Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者的角膜穿孔。
Am J Case Rep. 2023 Sep 1;24:e940688. doi: 10.12659/AJCR.940688.
4
Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience.贝伐单抗诱发卵巢癌患者关节痛及临床结局的回顾性分析。单中心经验。
Gynecol Oncol Rep. 2022 Mar 2;40:100953. doi: 10.1016/j.gore.2022.100953. eCollection 2022 Apr.
5
Ocular Toxicity of Targeted Anticancer Agents.靶向抗癌药物的眼部毒性。
Drugs. 2021 May;81(7):771-823. doi: 10.1007/s40265-021-01507-z. Epub 2021 Mar 31.
6
Radiation-induced neuropathies in head and neck cancer: prevention and treatment modalities.头颈部癌放疗所致神经病变：预防与治疗方式
Ecancermedicalscience. 2020 Nov 3;14:1133. doi: 10.3332/ecancer.2020.1133. eCollection 2020.
7
Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity.胶质母细胞瘤导致的视力丧失：类似假定治疗毒性的疾病。
Neurooncol Pract. 2018 Nov;5(4):223-226. doi: 10.1093/nop/npx037. Epub 2018 Feb 2.
8
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.分子靶向抗癌药物的神经眼科副作用。
Eye (Lond). 2018 Feb;32(2):287-301. doi: 10.1038/eye.2017.222. Epub 2017 Oct 20.
9
Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.神经肿瘤学会2014年年会关于中枢神经系统转移的最新情况
Neurooncol Pract. 2015 Jun;2(2):57-61. doi: 10.1093/nop/npv009. Epub 2015 Mar 24.
10
Photopsias during Systemic Bevacizumab Therapy.全身使用贝伐单抗治疗期间出现的光幻视
Case Rep Ophthalmol Med. 2016;2016:1926178. doi: 10.1155/2016/1926178. Epub 2016 Mar 16.
本文引用的文献
1
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.贝伐单抗单药及联合伊立替康治疗复发性胶质母细胞瘤。
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
2
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.贝伐单抗联合替莫唑胺及局部放射治疗用于新诊断多形性胶质母细胞瘤患者一线治疗的II期初步研究：安全性和耐受性的中期分析
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80. doi: 10.1016/j.ijrobp.2007.11.068. Epub 2008 Mar 20.
3
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.贝伐单抗治疗复发性恶性胶质瘤：疗效、毒性及复发模式
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.
4
Taming glioblastoma: targeting angiogenesis.驯服胶质母细胞瘤：靶向血管生成。
J Clin Oncol. 2007 Oct 20;25(30):4705-6. doi: 10.1200/JCO.2007.13.1037.
5
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.贝伐单抗联合伊立替康、氟尿嘧啶和亚叶酸钙治疗转移性结直肠癌。
N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.
6
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.一项关于抗血管内皮生长因子抗体贝伐单抗用于转移性肾癌的随机试验。
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
Zotero 插件